Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2 | P11137 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | BCKDK | O14874 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27784165 | 0.87 | GPR17 (0.47) | KDM4EALDH1A1KMT2APDPK1LMNA | |
| SCHEMBL6921821 | 0.83 | MAP2 (0.65) | MAP2KDM4EALDH1A1KMT2ALMNA | |
| SCHEMBL27531557 | 0.81 | MAP2 (0.52) | MAP2KDM4EMAPTALDH1A1CLK1 | |
| SCHEMBL2730323 | 0.81 | ALDH1A1 (0.59) | MAP2KDM4EMAPTALDH1A1CLK1 | |
| SCHEMBL3011277 | 0.80 | RXFP1 (0.61) | MAP2KDM4EMAPTALDH1A1CLK1 | |
| SCHEMBL3426959 | 0.80 | MAP2 (0.51) | MAP2KDM4EMAPTALDH1A1CLK1 | |
| SCHEMBL4334560 | 0.80 | MAP2 (0.55) | MAP2KDM4EMAPTALDH1A1CLK1 | |
| SCHEMBL15185062 | 0.80 | ALDH1A1 (0.61) | MAP2KDM4EMAPTALDH1A1KMT2A | |
| SCHEMBL17677402 | 0.80 | DAO (0.50) | KDM4EALDH1A1PDPK1LMNAHPGD | |
| SCHEMBL2730585 | 0.78 | MAPT (0.53) | MAP2KDM4EMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | disclosed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | disclosed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-1826333-B | Diamine derivatives | DAIICHI SANKYO CO LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| WO-2012059776-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2012-05-10 | — | — | WO | disclosed |
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-20040019015-A1 | Protection against and treatment of hearing loss | HEALTH RESEARCH, INC. (ROSWELL PARK DIVISION) | 2004-01-29 | — | — | US | disclosed |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-09-04 | — | — | US | disclosed |
| WO-2003035621-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-0167919-B1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| US-5004741-A | Cholecystokinin(CCK); Treating Disorders Of The Gastrointestinal Tract, Central Nervous System And Of The Appetite Of Animals | MERCK & CO., INC. (US) | 1991-04-02 | — | — | US | disclosed |
| US-4820834-A | Benzodiazepine analogs | MERCK & CO., INC. (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0284256-A1 | Benzodiazepine analogs | MERCK & CO. INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0167919-A2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | MAP2 1416/4885KDM4E 3663/4885MAPT 2040/4885 |
| US-20040019015-A1 | Protection against and treatment of hearing loss | NTRK2, AIFM2, AIFM1 | MAP2 1046/4885KDM4E 2603/4885MAPT 3734/4885 |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | MAP2 704/4885KDM4E 1359/4885MAPT 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.